Clinical trials: Superior Limbic Keratoconjunctivitis
Superior Limbic Keratoconjunctivitis
The Pathogenesis of Superior Limbic Keratoconjunctivitis
Superior limbic keratoconjunctivitis (SLK) was first described in detail as a clinical entity by Frederick Theodore in 1963. The clinical picture of SLK is well documented, but the etiology is still unknown.
- Trial name
- NCT00167050
- Where
- Taiwan
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Superior Limbic Keratoconjunctivitis, Conjunctivochalasis
The Role of Cytokines and Mast Cell in the Pathogenesis of SLK, Conjunctivochalasis, and Dry Eye
The specific aims of the the investigators studies are as follows: To collect the tear samples from patients with different ocular surface disorders, including SLK, conjunctivochalasis, and keratoconjunctivitis sicca (KCS).
- Conditions
- Superior Limbic Keratoconjunctivitis, Conjunctivochalasis, Dry Eye
- Trial name
- NCT02160327
- Where
- Taiwan
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- National Taiwan University Hospital
Superior Limbic Keratoconjunctivitis, Dry Eye Syndromes
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders
Dry eye disease, ocular graft-versus-host disease (GVHD), and superior limbic keratoconjunctivitis (SLK) are all ocular surface disorders which mostly involve the outer surface of the eye.
- Conditions
- Superior Limbic Keratoconjunctivitis, Dry Eye Syndromes, Graft Vs Host Disease
- Trial name
- NCT03731624
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation